vs
Side-by-side financial comparison of Celldex Therapeutics, Inc. (CLDX) and Alpha Teknova, Inc. (TKNO). Click either name above to swap in a different company.
Alpha Teknova, Inc. is the larger business by last-quarter revenue ($10.0M vs $120.0K, roughly 83.2× Celldex Therapeutics, Inc.). Alpha Teknova, Inc. runs the higher net margin — -47.7% vs -67764.2%, a 67716.5% gap on every dollar of revenue. On growth, Alpha Teknova, Inc. posted the faster year-over-year revenue change (7.8% vs -89.8%). Alpha Teknova, Inc. produced more free cash flow last quarter ($-810.0K vs $-65.2M). Over the past eight quarters, Alpha Teknova, Inc.'s revenue compounded faster (3.7% CAGR vs -12.3%).
Celldex Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops targeted immunotherapies for hard-to-treat cancers and rare immunological diseases. Its pipeline covers antibody-drug conjugates, monoclonal antibodies and other novel therapies, serving patients with high unmet medical needs mainly across North America and Europe.
Alpha Teknova, Inc. is a life sciences company that develops and manufactures specialized reagents, cell culture media, and custom laboratory solutions. It serves biopharmaceutical, molecular diagnostic, and academic research clients, primarily operating across the North American market to support drug discovery, diagnostic testing, and life science research workflows.
CLDX vs TKNO — Head-to-Head
Income Statement — Q4 2025 vs Q4 2025
| Metric | | |
|---|---|---|
| Revenue | $120.0K | $10.0M |
| Net Profit | $-81.3M | $-4.8M |
| Gross Margin | — | 32.5% |
| Operating Margin | -72628.3% | -46.2% |
| Net Margin | -67764.2% | -47.7% |
| Revenue YoY | -89.8% | 7.8% |
| Net Profit YoY | -72.7% | 16.8% |
| EPS (diluted) | $-1.23 | $-0.08 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $120.0K | $10.0M | ||
| Q3 25 | $0 | $10.5M | ||
| Q2 25 | $730.0K | $10.3M | ||
| Q1 25 | $695.0K | $9.8M | ||
| Q4 24 | $1.2M | $9.3M | ||
| Q3 24 | $3.2M | $9.6M | ||
| Q2 24 | $2.5M | $9.6M | ||
| Q1 24 | $156.0K | $9.3M |
| Q4 25 | $-81.3M | $-4.8M | ||
| Q3 25 | $-67.0M | $-4.3M | ||
| Q2 25 | $-56.6M | $-3.6M | ||
| Q1 25 | $-53.8M | $-4.6M | ||
| Q4 24 | $-47.1M | $-5.7M | ||
| Q3 24 | $-42.1M | $-7.6M | ||
| Q2 24 | $-35.8M | $-5.4M | ||
| Q1 24 | $-32.8M | $-8.1M |
| Q4 25 | — | 32.5% | ||
| Q3 25 | — | 30.7% | ||
| Q2 25 | — | 38.7% | ||
| Q1 25 | — | 30.7% | ||
| Q4 24 | — | 23.0% | ||
| Q3 24 | — | 0.9% | ||
| Q2 24 | — | 29.2% | ||
| Q1 24 | — | 23.8% |
| Q4 25 | -72628.3% | -46.2% | ||
| Q3 25 | — | -38.4% | ||
| Q2 25 | -8747.5% | -32.9% | ||
| Q1 25 | -9027.2% | -50.7% | ||
| Q4 24 | -4768.3% | -60.7% | ||
| Q3 24 | -1633.5% | -77.6% | ||
| Q2 24 | -1854.2% | -53.0% | ||
| Q1 24 | -26030.8% | -86.0% |
| Q4 25 | -67764.2% | -47.7% | ||
| Q3 25 | — | -41.0% | ||
| Q2 25 | -7753.4% | -34.7% | ||
| Q1 25 | -7740.4% | -47.4% | ||
| Q4 24 | -4007.8% | -61.7% | ||
| Q3 24 | -1320.0% | -79.0% | ||
| Q2 24 | -1434.8% | -55.8% | ||
| Q1 24 | -21030.8% | -87.2% |
| Q4 25 | $-1.23 | $-0.08 | ||
| Q3 25 | $-1.01 | $-0.08 | ||
| Q2 25 | $-0.85 | $-0.07 | ||
| Q1 25 | $-0.81 | $-0.09 | ||
| Q4 24 | $-0.71 | $-0.09 | ||
| Q3 24 | $-0.64 | $-0.15 | ||
| Q2 24 | $-0.54 | $-0.13 | ||
| Q1 24 | $-0.56 | $-0.20 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $518.6M | $21.3M |
| Total DebtLower is stronger | — | $13.1M |
| Stockholders' EquityBook value | $527.2M | $68.8M |
| Total Assets | $583.0M | $103.6M |
| Debt / EquityLower = less leverage | — | 0.19× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $518.6M | $21.3M | ||
| Q3 25 | $583.2M | $22.1M | ||
| Q2 25 | $630.3M | $24.0M | ||
| Q1 25 | $673.3M | $26.3M | ||
| Q4 24 | $725.3M | $30.4M | ||
| Q3 24 | $756.0M | $31.7M | ||
| Q2 24 | $802.3M | $18.6M | ||
| Q1 24 | $823.8M | $21.6M |
| Q4 25 | — | $13.1M | ||
| Q3 25 | — | $13.1M | ||
| Q2 25 | — | $13.0M | ||
| Q1 25 | — | $13.0M | ||
| Q4 24 | — | $9.4M | ||
| Q3 24 | — | $10.9M | ||
| Q2 24 | — | $12.3M | ||
| Q1 24 | — | $13.2M |
| Q4 25 | $527.2M | $68.8M | ||
| Q3 25 | $598.4M | $72.7M | ||
| Q2 25 | $655.4M | $76.1M | ||
| Q1 25 | $703.0M | $78.6M | ||
| Q4 24 | $747.0M | $82.4M | ||
| Q3 24 | $785.9M | $87.3M | ||
| Q2 24 | $813.7M | $78.9M | ||
| Q1 24 | $838.6M | $83.4M |
| Q4 25 | $583.0M | $103.6M | ||
| Q3 25 | $648.4M | $107.6M | ||
| Q2 25 | $692.4M | $110.5M | ||
| Q1 25 | $739.5M | $114.0M | ||
| Q4 24 | $792.3M | $118.8M | ||
| Q3 24 | $823.2M | $124.1M | ||
| Q2 24 | $845.6M | $115.4M | ||
| Q1 24 | $868.8M | $120.8M |
| Q4 25 | — | 0.19× | ||
| Q3 25 | — | 0.18× | ||
| Q2 25 | — | 0.17× | ||
| Q1 25 | — | 0.17× | ||
| Q4 24 | — | 0.11× | ||
| Q3 24 | — | 0.12× | ||
| Q2 24 | — | 0.16× | ||
| Q1 24 | — | 0.16× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-63.9M | $-462.0K |
| Free Cash FlowOCF − Capex | $-65.2M | $-810.0K |
| FCF MarginFCF / Revenue | -54350.8% | -8.1% |
| Capex IntensityCapex / Revenue | 1067.5% | 3.5% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-213.7M | $-9.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-63.9M | $-462.0K | ||
| Q3 25 | $-48.6M | $-2.0M | ||
| Q2 25 | $-44.0M | $-2.1M | ||
| Q1 25 | $-54.4M | $-4.1M | ||
| Q4 24 | $-32.5M | $-936.0K | ||
| Q3 24 | $-55.3M | $-2.1M | ||
| Q2 24 | $-29.3M | $-2.8M | ||
| Q1 24 | $-40.6M | $-6.6M |
| Q4 25 | $-65.2M | $-810.0K | ||
| Q3 25 | $-49.1M | $-2.4M | ||
| Q2 25 | $-44.7M | $-2.3M | ||
| Q1 25 | $-54.6M | $-4.3M | ||
| Q4 24 | $-33.2M | $-1.5M | ||
| Q3 24 | $-55.9M | $-2.4M | ||
| Q2 24 | $-29.6M | $-3.0M | ||
| Q1 24 | $-41.0M | $-6.7M |
| Q4 25 | -54350.8% | -8.1% | ||
| Q3 25 | — | -22.6% | ||
| Q2 25 | -6127.8% | -22.4% | ||
| Q1 25 | -7861.4% | -44.0% | ||
| Q4 24 | -2828.3% | -16.2% | ||
| Q3 24 | -1751.2% | -25.0% | ||
| Q2 24 | -1185.0% | -30.7% | ||
| Q1 24 | -26270.5% | -71.8% |
| Q4 25 | 1067.5% | 3.5% | ||
| Q3 25 | — | 3.7% | ||
| Q2 25 | 99.7% | 2.0% | ||
| Q1 25 | 38.1% | 2.1% | ||
| Q4 24 | 64.3% | 6.1% | ||
| Q3 24 | 17.1% | 3.5% | ||
| Q2 24 | 11.0% | 1.2% | ||
| Q1 24 | 220.5% | 1.2% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CLDX
Segment breakdown not available.
TKNO
| Lab Essentials | $6.8M | 68% |
| Clinical Solutions | $2.7M | 27% |
| Other | $435.0K | 4% |
